Somatostatin analog therapy for severe polycystic liver disease: results after 2 years (Q36208594)

12 August 2017

Somatostatin analog therapy for severe polycystic liver disease: results after 2 years (English)

1 reference

12 August 2017

polycystic liver disease

1 reference

Marie C Hogan

1

1 reference

12 August 2017

Tetyana V Masyuk

2

1 reference

12 August 2017

Linda Page

3

1 reference

12 August 2017

David R Holmes

4

1 reference

12 August 2017

Xujian Li

5

1 reference

12 August 2017

Eric J Bergstralh

6

1 reference

12 August 2017

Maria V Irazabal

7

1 reference

12 August 2017

Bohyun Kim

8

1 reference

12 August 2017

Bernard F King

9

1 reference

12 August 2017

James F Glockner

10

1 reference

12 August 2017

Nicholas F Larusso

11

1 reference

12 August 2017

Vicente E Torres

12

1 reference

12 August 2017

language of work or name

English

0 references

publication date

6 July 2012

1 reference

Nephrology Dialysis Transplantation

12 August 2017

1 reference

12 August 2017

27

1 reference

12 August 2017

9

1 reference

12 August 2017

3532-3539

1 reference

Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433774

Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433774

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433774

Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433774

The benefit of stereology for quantitative radiology

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433774

Identification of a locus for autosomal dominant polycystic liver disease, on chromosome 19p13.2-13.1

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433774

In vivo regulation of intraneuronal trafficking of G protein-coupled receptors for neurotransmitters

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433774

Somatostatin receptors in Neuro2A neuroblastoma cells: ligand internalization

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433774

Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433774

Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433774

Effects of long term octreotide on gall stone formation and gall bladder function

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433774

Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433774

New software toolkits for comprehensive visualization and analysis of three-dimensional multimodal biomedical images

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433774

Somatostatin inhibits excitatory transmission at rat hippocampal synapses via presynaptic receptors.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433774

Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433774

Severe hyperkalaemia resulting from octreotide use in a haemodialysis patient

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433774

Octreotide reduces hepatic, renal and breast cystic volume in autosomal-dominant polycystic kidney disease

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433774

Effect of octreotide on polycystic liver volume

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433774

Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433774

Somatostatin analogues reduce liver volume in polycystic liver disease

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433774

Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433774

Octreotide therapy for chylous ascites in a chronic dialysis patient

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433774

Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433774

Renal hemodynamic effects of somatostatin are not related to inhibition of endogenous insulin release

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433774

Complications associated with Ommaya reservoirs in patients with cancer. The Princess Margaret Hospital experience and a review of the literature

22 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FNDT%2FGFS152

Carcinoid tumour management in haemodialysis: a case report

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22773240

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/NDT/GFS152

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

22773240

1 reference